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A 58-year-old woman was diagnosed with peritoneal epithelioid mesothelioma, postdebulking surgery. Peripheral blood showed neutrophilic leukocytosis with left-shifted granulopoiesis, anemia, and mild thrombocytosis (white blood cells [WBCs], 89 3 10 9 /L; hemogloblin [Hb], 6.0 g/dL; platelets, 617 3 10 9 /L). Four months later, she presented to our institution with liver metastasis, progressive marked left-shifted neutrophilic leukocytosis, and anemia (WBCs, 284 3 10 9 /L; absolute neutrophil count, 272 3 10 9 /L; Hb, 7.4 g/dL; platelets, 145 3 10 9 /L) (panels Cytogenetic analysis showed diploid female karyotype. Fluorescence in situ hybridization was negative for BCR-ABL1. Nextgeneration sequencing (81-gene panel) including CSF3R/JAK2/ CALR/MPL and SETBP1 showed no mutations. Thus, overall findings were in keeping with a marked paraneoplastic leukemoid reaction (LR) in response to metastatic mesothelioma.
LR is reactive/paraneoplastic left-shifted neutrophilic leukocytosis (WBCs, .50 3 10 9 /L), and can mimic MN. Marked LR in the setting of mesothelioma is exceedingly rare and can be idiopathic or attributed to cytokine production (G-CSF/granulocyte macrophage colony-stimulating factor/interleukin-6) by tumor cells. This case highlights the comprehensive approach of correlating clinical presentation with morphology (no dysplasia, atypical megakaryocytes or abnormal monocytes, presence of Döhle bodies), flow cytometry (no aberrant myeloblasts/ abnormal myeloid maturation), and absence of clonality by cytogenetic and molecular studies, helping to distinguish reactive marked LR from MNs.
